RemeGen Co (HKSE:09995) Change In Working Capital : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Change In Working Capital?

RemeGen Co's change in working capital for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

RemeGen Co's change in working capital for the fiscal year that ended in Dec. 2023 was HK$-391.9 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

RemeGen Co Change In Working Capital Historical Data

The historical data trend for RemeGen Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Change In Working Capital Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

28.78

-138.15

-205.91

-584.76

-391.93

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial									-	-	-	-	-

RemeGen Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

RemeGen Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Wang Xudong	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Liqiang	2103 Interests held jointly with another person
I-nova Limited	2101 Beneficial owner
Lin Jian	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines